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The advances in organic synthesis and the intensive use of pharmaceuticals have led to the 
introduction of numerous of these compounds in the environment, whose susceptibilities to 
biotreatment processes are unknown. Pharmaceuticals can reach the environment through 
excretion in the original chemical structure or as metabolites and through improper elimination 
or disposal (Corcoran et al., 2010). Their occurrence, especially in aquatic environments, is of 
great concern because of their potential to cause ecosystem alteration (Santos et al., 2010). 
Currently, the conventional wastewater treatment plants (WWTPs) are not designed and 
operated to remove pharmaceuticals. As a result, residues of these compounds have been 
detected in aquatic ecosystems in low concentrations ranging from the ng/L up to the µg/L level 
(Kümmerer, 2009). In this context, the present work aimed to investigate the potential of two 
different microbial consortia to biodegrade five pharmaceuticals, belonging to three different 
therapeutic classes, commonly used and present in wastewaters: the antibiotics - trimethoprim
(TMP), sulfamethoxazole (SMX) and ciprofloxacine (CPF), the anti-epileptic - carbamazepine
(CBZ) and the anti-inflammatory – diclofenac (DCF) (Fig. 1).
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Figure 1. Chemical structure of the studied pharmaceuticals.
Experiments conducted in duplicate and in batch mode.
Abiotic degradation assays performed by supplementing MM with a 
mixture containing 10 µg/mL of each pharmaceutical, without inoculation 
of any consortium. 
Activated sludge showed a significant capacity to degrade SMX and 
some capacity to degrade the others pharmaceuticals tested, with removal 
efficiency values always higher than 30%.
Acetate showed to not have a strong influence in the pharmaceuticals 
biodegradation pattern by both consortia.
25 μg/ml of the target pharmaceutical supplied individually
Cultures incubated at 100 rpm at 25ºC, for two weeks
Centrifuged at 14000 rpm for 5 min
Analysis of the supernatant by HPLC-DAD
Figure 2. Schematic representation of biodegradation assays .
Figure 3. Biodegradation pattern of the target pharmaceuticals by activated 
sludge (CAS) and the FB degrading consortium (CFB).
The FB degrading consortium was only able to slightly remove CPF and 
CBZ. 
Biodegradation assays conducted with two different microbial 
consortia: activated sludge obtained from a WWTP (Parada, Portugal) 
and one microbial consortium capable to degrade recalcitrant 
compounds, such as fluorobenzene (FB).
None of the tested consortia was able to completely degrade the target 
pharmaceuticals.
